LIXTE BIOTECHNOLOGY HOLDINGS, INC. Material Event: Strategic Pivot and Acquisition

Lixte Biotechnology has signed a deal to acquire Nomad Transportable Power Systems, Inc. Once the deal closes, Lixte will rebrand as NOMAD Power Solutions. This marks a complete shift in the company’s business model: it is moving away from cancer drug research and into the deployment of mobile, utility-grade battery energy storage systems.

1. What is changing?

Lixte is transitioning from a pharmaceutical company—previously focused on its lead cancer drug, LB-100—to an energy infrastructure provider. The new entity, NOMAD Power Solutions, will focus on mobile battery systems designed to provide power where and when it is needed most.

2. Why is this happening?

Lixte’s leadership identified a massive "power availability crisis" driven by the energy-hungry demands of artificial intelligence, data centers, electric vehicle charging, and manufacturing.

Traditional battery storage projects are often stationary and bogged down by years of land permitting, environmental reviews, and grid connection delays. Nomad’s competitive edge is its transportable technology. Because their systems are mobile equipment, they can be deployed much faster than traditional infrastructure, allowing the company to bypass the typical multi-year wait times.

3. Why does this matter for your investment?

This deal is a total transformation. Your investment is shifting from a high-risk, long-term biotech research play to an infrastructure-growth model.

• Growth Potential: Nomad is scaling rapidly. Revenue reportedly jumped about 175% in 2025, with management projecting another 135% increase in 2026.
• The "Cash" Hurdle: The merger is contingent on Lixte holding at least $16.5 million in cash at the time of closing. This is intended to ensure the new company has the capital required to scale Nomad’s operations immediately.
• Leadership Overhaul: The deal requires a complete replacement of the Board of Directors and executive team to align with the new focus on energy systems.

4. What should you watch for?

• The Shareholder Vote: Keep an eye out for the upcoming proxy statement. Shareholders will be asked to vote on the issuance of new preferred stock and the election of the new Board of Directors.
• The Pivot: If you originally invested in LIXT for its cancer research (specifically LB-100), you should evaluate whether this new energy-sector business model still aligns with your personal investment goals.
• Closing Conditions: The deal has an "Outside Date" of 120 days from signing. If the required conditions—including the $16.5 million cash threshold—are not met by this deadline, either party can walk away.

5. Final Takeaway for Investors

This is no longer a biotech stock. It is becoming an energy infrastructure stock. The value of your investment will now be tied to the company's ability to deploy mobile power systems and capture market share in the data center and AI energy space.

Before making a decision, look for the upcoming proxy statement to understand the specific strategy of the new leadership team and how they plan to integrate Nomad’s technology into the public company structure.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and should not be taken as professional investment advice. Always do your own research and consult with a qualified financial advisor before buying or selling stocks.